logo
From Costco to clinics: New health-care centre opening in east end of St. John's this fall

From Costco to clinics: New health-care centre opening in east end of St. John's this fall

CBC2 days ago
A new health-care facility will open in the former Costco building in St. John's in October, offering urgent care and outpatient appointments.
People may know it as the former Costco building, but "it looks nothing like that now," Health Minister Krista Lynn Howell told reporters during a tour of the site on Tuesday.
Howell said the new urgent- and ambulatory-care centre at 28 Stavanger Drive is opening in phases this fall and is expected to shorten hospital wait times.
The urgent care centre will treat people with non-life threatening injuries and illnesses — such as minor sprains and strains. It's meant to relieve pressure on emergency rooms, said Howell, so ERs can focus on "true emergencies."
Several outpatient services are also opening at the ambulatory-care centre in October, relocating from the Health Sciences Centre and St. Clare's Mercy Hospital. These include several specialist clinics and two X-ray machines, orthopedics, audiology, and appointment scheduling and registration, said a Newfoundland and Labrador Health Services statement.
More services are scheduled to move to the site in December, including physiotherapy, blood collection, occupational therapy, surgery preadmission clinic, pain clinic, ultrasound and an additional X-ray machine.
MRI services are set to open in 2026.
There will be an information campaign in the fall to let people know where they should go for different health issues, said Greg Browne, a vascular surgeon and the clinical lead for healthcare infrastructure.
Once you're inside the building, Howell said clear signs will make it easier for people to know where their appointments are.
"I think as patients we're going to really see the benefits of this once we start using it," said Dorothy Senior, a patient advisor who sits on committees for the health authority.
She listed the benefits of having access to all clinics in one area, colour coding, and having comfortable places to sit.
In its statement, the health authority said the hub will have free parking for patients and staff, as well as an outdoor space. A pharmacy and Jumping Bean coffee shop are set to open there next year, and there are plans underway for a daycare provider.
The project is coming in on budget, said Kimberley Pike, clinical planner with Provincial Capital Planning. The province is renting the old Costco site, which hasn't been used since 2019.
"Clinic appointments and ambulatory appointments really don't need to happen in an acute care hospital, with all the hustle and bustle and the stress that people go through by going into a hospital environment," said Pike.
In its statement, the health authority said some outpatient services will still remain at the hospitals. Ear, nose and throat clinics, as well as rheumatology, will also stay at St. Clare's Mercy Hospital.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

OptimizeRx Sets Second Quarter 2025 Conference Call for August 7, 2025, at 4:30 p.m. ET
OptimizeRx Sets Second Quarter 2025 Conference Call for August 7, 2025, at 4:30 p.m. ET

Globe and Mail

timean hour ago

  • Globe and Mail

OptimizeRx Sets Second Quarter 2025 Conference Call for August 7, 2025, at 4:30 p.m. ET

WALTHAM, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the 'Company') (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, August 7, 2025, at 4:30 p.m. Eastern Time to discuss its results for the second quarter period ended June 30, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Please call the conference telephone number or log on to the web access link five minutes prior to the start time. A replay of the call will remain available for 12 months via the Investors section of the OptimizeRx website at About OptimizeRx OptimizeRx is a leading healthcare technology company that's redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes. Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world's leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.

Elucid Names Richard E. Kuntz, MD, MSc and Shamiram Feinglass, MD, MPH Board Directors
Elucid Names Richard E. Kuntz, MD, MSc and Shamiram Feinglass, MD, MPH Board Directors

National Post

timean hour ago

  • National Post

Elucid Names Richard E. Kuntz, MD, MSc and Shamiram Feinglass, MD, MPH Board Directors

Article content BOSTON & SCCT ANNUAL MEETING, MONTREAL — Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, has made two additions to its Board of Directors. The company named Richard E. Kuntz, MD, MSc and Shamiram Feinglass, MD, MPH as board directors. Article content These appointments will help guide Elucid as it accelerates its clinical research strategy, commercializes its flagship PlaqueIQ TM coronary plaque assessment technology, and continues development of its investigational FFR prediction model, based on PlaqueIQ. PlaqueIQ is the first and only FDA-cleared, non-invasive plaque analysis based on objective histology rather than subjective CCTA visual estimates. PlaqueIQ quantifies and classifies plaque morphology based on ground-truth histology, the gold standard for characterization of plaques. The software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk. Article content An experienced medical technology executive and clinical expert, Dr. Kuntz is former senior vice president and chief medical and scientific officer of Medtronic plc. Prior to joining Medtronic, he was the founder and chief scientific officer of the Harvard Clinical Research Institute (HCRI), a university-based contract research organization that coordinates National Institutes of Health (NIH) and industry clinical trials with the U.S. Food and Drug Administration (FDA). Dr. Kuntz has directed several multicenter clinical trials and has authored more than 250 original publications. Dr. Kuntz was an associate professor of Medicine at Harvard Medical School, chief of the division of Clinical Biometrics, and an interventional cardiologist in the division of cardiovascular diseases at the Brigham and Women's Hospital in Boston. Article content Dr. Feinglass is a managing director at Manatt Health working across the business, medical, and policy needs of health systems, life sciences, medical device, digital health and diagnostic companies globally. A global leader in health care, Dr. Feinglass has served as an executive and chief medical officer in large multi-national life sciences corporations including Danaher and Zimmer-Biomet. In parallel, she has driven policy changes alongside senior government officials around the world to influence health policy, regulation, and access. A former regulator at U.S. Centers for Medicare and Medicaid Services (CMS) and commander in the U.S. Public Health Service with extensive regulatory and legislative experience, Dr. Feinglass is on faculty at the John's Hopkins Bloomberg School of Public Health, Department of Mental Health and is a member of the Board of Directors of Sandoz AG. Article content 'We are honored that Dr. Richard E. Kuntz and Dr. Shamiram Feinglass have joined Elucid's Board of Directors,' said Elucid CEO Kelly Huang, PhD. 'Rick lends an important and experienced interventional cardiology view, as well as expertise in clinical trial strategy and execution, and product innovation strategy. Coupled with Shami's unparalleled expertise in market access, policy making, and regulatory strategy, the two will be invaluable as we push forward our vision of a future where cardiac care is personalized, precision patient care versus risk factor and population-based care.' Article content About Elucid Article content Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary plaque buildup), the root cause of cardiovascular disease. The company's PlaqueIQ TM image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. PlaqueIQ includes the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque, as indicated by renowned pathologists. PlaqueIQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFR CT, derived from its plaque algorithm, to help identify coronary blockages and the extent of ischemia non-invasively. For more information, visit Article content Article content Article content Article content Contacts Article content Media Contact: Article content Article content Sam Choinski Article content Article content Article content Article content

Aveanna Announces Second Quarter 2025 Earnings Release Date and Conference Call
Aveanna Announces Second Quarter 2025 Earnings Release Date and Conference Call

Globe and Mail

time2 hours ago

  • Globe and Mail

Aveanna Announces Second Quarter 2025 Earnings Release Date and Conference Call

ATLANTA, July 17, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. ('Aveanna') (NASDAQ: AVAH) today announced that the company will release its second quarter results before the market open on Thursday, August 7, 2025, to be followed by a conference call at 10:00 a.m. (Eastern Time) on the same day. The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available three hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13754011. The replay will be available until August 14, 2025. Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of the Company's website at The online replay will be available for one week following the call. About Aveanna Healthcare Aveanna Healthcare is headquartered in Atlanta, Georgia and has locations in 36 states providing a broad range of pediatric and adult healthcare services including nursing, rehabilitation services, occupational nursing in schools, therapy services, day treatment centers for medically fragile and chronically ill children and adults, home health and hospice services, as well as delivery of enteral nutrition and other products to patients. The Company also provides case management services in order to assist families and patients by coordinating the provision of services between insurers or other payers, physicians, hospitals, and other healthcare providers. In addition, the Company provides respite healthcare services, which are temporary care provider services provided in relief of the patient's normal caregiver. The Company's services are designed to provide a high quality, lower cost alternative to prolonged hospitalization. For more information, please visit

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store